trial · primary record
epcoritamab
Waldenstrom Macroglobulinemia
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 24 |
| Primary completion | 2033-11-01 |
| Primary endpoint | Rate of complete remission (CR) or very good partial remission (VGPR) |
| Registry ID | NCT07882173 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:29.029Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07882173
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.